# US 2026/0275381 A1 · Adeno-associated virus vector encoding connexin 26 and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0275381 A1
- Document ID: US20260275381A1
- Status: Published application
- Kind: A1
- Application number: 19/168,065
- Filed: 2024-03-28
- Published: 2026-09-17
- Earliest claimed: 2023-03-28
- Applicants: Sensorion; Institut Pasteur
- Inventors: Laurent DESIRE; Arnaud GIESE; Patrice VIDAL; Christine PETIT; Anne-Valerie HERITIER; Nicolas MICHALSKI
- Web page: https://patentgrep.com/patent/US20260275381A1

## CPC

- C12N 15/86: Viral vectors
- C12N 15/8645: {Adeno-associated virus}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- A61P 27/16: Otologicals
- C07K 14/015: Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
- C07K 14/47: from mammals
- A01K 2217/075: inducing loss of function, i.e. knock out
- A01K 2217/206: Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
- A61K 48/0066: {Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid}
- C12N 2750/14032: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14171: Demonstrated in vivo effect
- C12N 2830/00: Vector systems having a special element relevant for transcription
- C12N 2830/34: being a transcription initiation element
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

## Abstract

The present invention relates to a recombinant adeno-associated virus (rAAV) vector encoding connexin 26 (CX26). The present invention further relates to the use of said AAV vector in the treatment of genetic hearing loss.

## Claims

### Claim at position 1

1-15. (canceled)

### Claim 16

An adeno-associated virus (AAV) vector comprising a capsid being an AAV-DJ capsid or being derived from an AAV-DJ capsid, wherein the AAV vector comprises a polynucleotide comprising (i) a nucleic acid sequence encoding a connexin 26 protein (CX26) operably linked to a promoter and (ii) at least one copy of a miRNA target site of the miR183 family comprising a sequence as set forth in SEQ ID NO: 3, SEQ ID NO: 16, or SEQ ID NO: 31, or a sequence having at least 90% identity with any one of SEQ ID NO: 3, SEQ ID NO: 16, or SEQ ID NO: 31.

### Claim 17 (depends on 16)

The AAV vector according to claim 16, comprising two to six copies of the miRNA target site of the miR183 family comprising a sequence as set forth in SEQ ID NO: 3, SEQ ID NO: 16, or SEQ ID NO: 31, or a sequence having at least 90% identity with any one of SEQ ID NO: 3, SEQ ID NO: 16, or SEQ ID NO: 31.

### Claim 18 (depends on 16)

The AAV vector according to claim 16, comprising three copies of the miRNA target site of the miR183 family comprising a sequence as set forth in SEQ ID NO: 3, SEQ ID NO: 16, or SEQ ID NO: 31, or a sequence having at least 90% identity with any one of SEQ ID NO: 3, SEQ ID NO: 16, or SEQ ID NO: 31.

### Claim 19 (depends on 16)

The AAV vector according to claim 16, wherein the promoter is a smCBA promoter.

### Claim 20 (depends on 16)

The AAV vector according to claim 16, wherein the connexin 26 protein is human CX26.

### Claim 21 (depends on 16)

The AAV vector according to claim 16, wherein the polynucleotide further comprises a 5′ and a 3′ inverted terminal repeats (ITRs).

### Claim 22 (depends on 16)

The AAV vector according to claim 16, wherein the polynucleotide further comprises at least one copy of another miRNA target site selected from the miR183 family.

### Claim 23 (depends on 16)

A pharmaceutical composition comprising the AAV vector according to claim 16, and at least one pharmaceutically acceptable excipient or carrier.

### Claim 24 (depends on 16)

A medicament comprising the AAV vector according to claim 16.

### Claim 25 (depends on 16)

A method for the treatment of genetic hearing loss in a subject in need thereof, said method comprising administering to the subject a therapeutically effective dose of the AAV vector according to claim 16.

### Claim 26 (depends on 25)

The method according to claim 25, wherein the genetic hearing loss is non-syndromic hearing loss and deafness (DFNB1).

### Claim 27 (depends on 25)

The method according to claim 25, wherein the genetic hearing loss is profound genetic hearing loss.

### Claim 28 (depends on 25)

The method according to claim 25, wherein the genetic hearing loss is severe genetic hearing loss.

### Claim 29 (depends on 25)

The method according to claim 25, wherein the genetic hearing loss is progressive genetic hearing loss.

### Claim 30 (depends on 25)

The method according to claim 25, wherein the subject is an adult.

### Claim 31 (depends on 25)

The method according to claim 25, wherein the subject is an infant or a child.
